# DESCRIPTION

## FIELD OF THE INVENTION

- relate to pharmaceutical compositions

## BACKGROUND OF THE AND INVENTION

- motivate proliferative disorders
- explain protein kinase activity
- describe limitations of PKIs
- discuss formulation chemistry
- summarize methods to improve dissolution
- highlight need for improved dissolution

## SUMMARY OF THE INVENTION

- introduce amorphous hybrid nanoparticles

## DETAILED DESCRIPTION OF THE INVENTION

- define hybrid nanoparticles
- describe properties of hybrid nanoparticles
- define solid dispersion particles
- explain stability of hybrid nanoparticles
- define protein kinase inhibitor (PKI)
- describe polymeric stabilizing and matrix-forming component
- define solubilizer
- explain primary particles and agglomeration
- define various terms related to solubility and dissolution
- define PKIs and related terms
- define water-insoluble compounds
- describe formation of hybrid nanoparticles
- describe continuous processes for generating hybrid nanoparticles
- describe precipitation methods
- describe the "Right Size system"
- describe the system components and operation
- describe particle formation and separation
- describe system setup and operation
- describe particle collection and drying
- describe solution and antisolvent properties
- describe antisolvent selection and properties
- describe pharmaceutical composition
- describe solubilizer properties and distribution
- describe increased dissolution rate
- describe dissolution rate measurement
- describe solubility increase
- list polymeric stabilizing and matrix-forming components
- specify polymeric stabilizing and matrix-forming components
- describe composition with stable, amorphous hybrid nanoparticles
- specify protein kinase inhibitor
- describe dissolution rate of stable, amorphous hybrid nanoparticles
- specify average particle diameter size
- describe solvent selection
- describe systemic absorption of protein kinase inhibitor
- specify pH conditions for systemic absorption
- describe measurement of systemically absorbed protein kinase inhibitor
- describe solubility increase of inhibitor
- specify pH range for in vitro dissolution testing
- describe solution preparation for in vitro dissolution testing
- specify amount of PKI in hybrid nanoparticles
- describe control of particle characteristics
- describe pharmaceutical compositions comprising stable, amorphous hybrid nanoparticles
- specify solubilizer selection
- describe pharmaceutical composition with multiple layers
- specify inhibitor and polymeric stabilizing and matrix-forming component combinations
- describe pharmaceutical composition for therapy
- describe pharmaceutical composition for treating proliferative disorders
- describe method of treating proliferative disorder
- describe dosage and administration of pharmaceutical composition

## EXAMPLES

- introduce compositions comprising stable, amorphous hybrid nanoparticles
- describe production method of stable, amorphous hybrid nanoparticles
- outline dissolution measurement assay

### General Description of Dissolution Measurement Assay

- describe dissolution measurement assay

### Example 1

- describe experiments with nilotinib base or nilotinib HCl
- present results in FaSSIF and FeSSIF solutions
- conclude solubility increase with stable, amorphous hybrid nanoparticles

### Example 2

- describe experiments with erlotinib HCl
- present results in FaSSIF and FeSSIF solutions
- conclude solubility increase with stable, amorphous hybrid nanoparticles

### Example 3

- describe experiments with pazopanib
- present results in FaSSIF and FeSSIF solutions
- conclude solubility increase with stable, amorphous hybrid nanoparticles

### Example 4

- describe experiments with lapatinib base or lapatinib ditosylate salt

### Example 5

- describe experiments with nilotinib HCl in SGF solution

### Example 6

- describe experiments with gefitinib

### Example 7

- describe experiments with dasatinib

### Example 8

- conduct experiments with sorafenib tosylate
- measure concentration of PKI after 3, 40, and 80 minutes dissolution
- provide representative results in FaSSIF solution
- show solubility increase with compositions comprising stable, amorphous hybrid nanoparticles
- achieve particular improvements with HPMCP HP55
- achieve further improvements with Soluplus
- conduct experiments with nilotinib base
- measure concentration of PKI after 3, 40, and 80 minutes dissolution
- provide representative results in FaSSIF solution
- show solubility increase with compositions comprising stable, amorphous hybrid nanoparticles
- achieve particular improvements with PVP 30K and Kollidon VA64
- achieve further improvements with Soluplus and Cremophor RH40
- conduct experiments with crizotinib, axitinib, vemurafenib, and other PKIs
- introduce dissolution rate measurement
- compare dasatinib raw form with hybrid nanoparticles
- compare sorafenib tosylate raw form with hybrid nanoparticles
- compare crizotinib raw form with hybrid nanoparticles
- compare axitinib raw form with hybrid nanoparticles
- compare vemurafenib raw form with hybrid nanoparticles
- describe in vivo measurement of plasma levels
- present results and conclusions of in vivo study
- describe measurement of degree of stability of compositions
- present results of stability tests
- describe modulated differential scanning calorimetry
- describe thermogravimetry
- describe dynamic vapor sorption
- describe X-ray powder diffraction and dissolution rate measurement

